The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Papaverine Hydrochloride
Papaverine Hydrochloride · PAPAVERINE HYDROCHLORIDE 30 mg/mL · Injection, Solution · Intravenous · Oryza Pharmaceuticals Inc.
NDC 72516-0024-10 · 10 VIAL in 1 CARTON / 2 mL in 1 VIAL · UNAPPROVED DRUG OTHER · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$388.66
Reported to Texas DSHS · 2026 annual filing · Oryza Pharmaceutical
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · TerminatedMar 14, 2022Vitae Enim Vitae Scientific, Inc. — Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Manufacturers of Papaverine Hydrochloride (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| American Regent, Inc. | PAPAVERINE HYDROCHLORIDE 30 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| BPI Labs LLC | PAPAVERINE HYDROCHLORIDE 30 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Oryza Pharmaceuticals Inc. | PAPAVERINE HYDROCHLORIDE 30 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Papaverine Hydrochloride — NDC 72516-0024-10," retrieved September 3, 2026, https://drugdashboards.com/drug/72516002410.
Free to cite with attribution — see how the data is put together.